Cardiopulmonary exercise testing (CPET) provides important information for the assessment and management of patients with heart failure. This testing measures the respiratory and cardiac responses to exercise and allows measurement of the oxygen uptake (O2) max and the relationship between minute ventilation (E) and carbon dioxide excretion (CO2). These two parameters help classify patients into categories that help predict prognosis, and patients with a O2 < 14 mL/kg/min and E/CO2 slope >35 have a poor prognosis. This testing has been used in drug trials to determine complex physiologic responses to medications, such as angiotensin-converting enzyme inhibitors. For example, a study with enalapril demonstrated that the peak O2 was 14.6 ± 1.6 mL/kg/min on placebo and 15.8 ± 2.0 mL/kg/min on enalapril after 15 days of treatment. The E/CO2 slopes were 43 ± 8 on placebo and 39 ± 7 on enalapril. Chronic heart failure and reduced physical activity measured by cardiopulmonary exercise testing are associated with increases in BNP, and several studies have demonstrated that cardiac rehabilitation is associated with reductions in BNP and increases in O2. Therefore, BNP measurements can help determine the benefits of cardiac rehabilitation and provide indirect estimates of changes in O2. In addition, measurement of microRNAs can determine the status of skeletal muscle used during physical activity and the changes associated with rehabilitation. However, CPET requires complicated technology, and simpler methods to measure physical activity could help clinicians to manage their patients. Recent advances in technology have led to the development of portable cardiopulmonary exercise testing equipment, which can be used in various routine physical activities, such as walking upstairs, sweeping the floor, and making the bed, to provide patients and clinicians a better understanding of the patient’s current symptoms. Finally, current smart watches can provide important information about the cardiorespiratory system, identify unexpected clinical problems, and help monitor the response to treatment. The organized use of these devices could contribute to the management of certain aspects of these patients’ care, such as monitoring the treatment of atrial fibrillation. This review article provides a comprehensive overview of the current use of CPET in heart failure patients and discusses exercise principles, methods, clinical applications, and prognostic implications.
12 May 2025 in Catheterization and Cardiovascular Interventions
Background: Coronary artery vasospasm following coronary artery bypass grafting (CABG) is a rare but potentially life‐threatening complication that can lead to myocardial ischemia, arrhythmias, and cardiogenic shock. Nitroglycerin‐resistant vasospasm, particularly involving the left main coronary artery (LMCA), poses significant diagnostic and therapeutic challenges. Case Presentation: We report the case of a 47‐year‐old female with a history of hypertension, hyperlipidemia, and ADHD on dextroamphetamine‐amphetamine, who presented with chest pain and was found to have a suspected severe LMCA lesion. Coronary angiography revealed a 95% LMCA stenosis that was unresponsive to intracoronary nitroglycerin, raising concern for catheter‐induced vasospasm versus true stenosis. The patient underwent urgent CABG. Intraoperatively and postoperatively, she experienced recurrent, diffuse coronary vasospasm refractory to nitroglycerin, necessitating multiple interventions including mechanical circulatory support with intra‐aortic balloon pump and percutaneous ventricular assist device. Coronary angiography confirmed severe diffuse coronary and peripheral vasospasm. The patient was managed with intravenous vasodilators, vasopressors, and supportive care, and eventually recovered with restoration of cardiac function and discharge to cardiac rehabilitation. Discussion: This case underscores the difficulty in differentiating vasospasm from true atherosclerotic disease in the LMCA, the potential for nitroglycerin resistance, and the risk of severe complications during CABG. The use of adjunctive imaging modalities, vasodilators beyond nitroglycerin, and early mechanical circulatory support may be critical in managing such complex cases. Conclusion: Nitroglycerin‐resistant coronary vasospasm, especially in the LMCA, can mimic fixed stenosis and lead to inappropriate surgical intervention and life‐threatening complications. A multidisciplinary, imaging‐guided approach is essential for accurate diagnosis and optimal management.
Platypnea‐orthodeoxia syndrome is a rare disorder characterized by dyspnea (platypnea) and arterial desaturation (orthodeoxia) in the upright position, with symptom relief upon lying down. This syndrome is commonly associated with cardiac anomalies, particularly patent foramen ovale (PFO), where increased right atrial pressure facilitates right‐to‐left shunting, leading to hypoxemia. Other associated conditions include cirrhosis, pericardial effusion, and pneumonectomy. We present a 32‐year‐old female with a history of right pneumonectomy for invasive aspergillosis who presented with worsening dyspnea and a greater than 10% drop in SpO2 when seated compared to the supine position. Initial imaging demonstrated rightward displacement of thoracic structures, including the right atrium, but a transthoracic echocardiogram was negative for intracardiac shunt. Due to persistent hypoxemia, a transesophageal echocardiogram was performed, revealing a right‐to‐left shunt, an atrial septal aneurysm, and a prominent Eustachian valve. The patient underwent successful PFO closure, leading to the complete resolution of both dyspnea and hypoxemia. This case emphasizes the importance of comprehensive diagnostic evaluation in patients with POS, especially those with complex cardiopulmonary histories.
Type 2 myocardial infarction (T2MI) results from myocardial oxygen supply–demand imbalance in the absence of acute atherothrombotic plaque rupture and is associated with substantial short-term and long-term mortality. Although increasingly recognized with the widespread use of high-sensitivity cardiac troponin assays, optimal pharmacologic management of T2MI remains poorly defined. We performed a narrative review evaluating pharmacologic treatment patterns and outcomes in adults with adjudicated or clinically coded T2MI. Evidence consistently demonstrates a high prevalence of underlying coronary artery disease in T2MI, with up to two-thirds of patients exhibiting significant coronary artery stenosis. Despite this overlap with ischemic heart disease, prescription rates of antiplatelet agents, statins, β-blockers, and renin–angiotensin–aldosterone system inhibitors are substantially lower in T2MI compared with type 1 myocardial infarction. Observational data suggest that statins, β-blockers, renin–angiotensin–aldosterone system inhibitors, and combination secondary prevention strategies may be associated with improved survival, whereas evidence supporting routine antiplatelet or anticoagulant therapy remains limited and inconsistent. Overall, T2MI represents a high-risk and underrecognized clinical entity for which pharmacologic management is largely extrapolated from type 1 myocardial infarction and coronary artery disease. Prospective, T2MI-focused studies are urgently needed to define optimal secondary prevention strategies and improve clinical outcomes.
Background: In severe aortic stenosis patients undergoing TAVR, whether coexisting coronary disease prompts revascularization and its optimal timing remain unclear. Aim: To evaluate the efficacy and safety of PCI before TAVR compared to deferred PCI in patients with severe aortic stenosis and concomitant coronary artery disease. Methods: We performed a meta-analysis of RCTs. PubMed, Embase, Scopus, CENTRAL, and Web of Science were searched for RCTs comparing PCI before TAVR versus no PCI. HRs with 95% CIs were pooled using random-effects models. Results: Three RCTs (ACTIVATION, NOTION-3, PRO-TAVI) enrolling 1,156 patients (579 PCI, 577 no-PCI) were included. Routine PCI before TAVR did not reduce all-cause mortality (HR 0.88, 95% CI 0.67–1.17; p=0.38) or cardiovascular death (HR 0.77, 95% CI 0.49–1.19; p=0.23). PCI significantly reduced any revascularization (HR 0.24, 95% CI 0.06–0.86; p=0.029), and urgent revascularization (HR 0.33, 95% CI 0.12–0.87; p=0.025). MI was not significantly reduced with PCI (HR 0.84, 95% CI 0.44–1.59; p = 0.59). Stroke showed a borderline trend favoring PCI (HR 0.69, 95% CI 0.46–1.04; p=0.073). PCI significantly increased any bleeding (HR 1.96, 95% CI 1.28–3.0; p=0.002) and major bleeding (HR 1.88, 95% CI 1.07–3.31, p=0.027). Neither AKI nor rehospitalization differed significantly between groups. Leave-one-out sensitivity analyses confirmed the stability of mortality, stroke, and bleeding estimates. Conclusions: Routine PCI before TAVR does not reduce mortality. It lowers urgent revascularization and trends toward less stroke but nearly doubles bleeding. Findings support selective, individualized PCI rather than routine revascularization before TAVR.